Avacta

Accelerated Amortized Payment of Convertible Bond Installment. avacta.com/accelerated-am… #AVCT

We’re delighted to welcome Dr. Patrick Vink to Avacta’s Board as Non-Executive Deputy Chairman and Senior Independent Director. Patrick brings decades of pharma leadership at a key time for our pre|CISION® pipeline. avacta.com/avacta-appoint… #AVCT

BIO International 2026: Faridoxorobicin update with Avacta CEO @coughlin582. avacta.wistia.com/s/xi4ktvnhpkyo… #AVCT

Avacta Reports Platform-Validating Data with Faridoxorubicin during BIO International Conference. avacta.com/avacta-reports… #AVCT

Avacta Announces U.S. FDA Agreement on Pivotal Trial Design for AVA6000 in Patients with Salivary Gland Cancer. avacta.com/avacta-announc… #AVCT

Avacta today announces that all resolutions were duly passed by shareholders at the Annual General Meeting which was held on Monday June 22. avacta.com/result-of-agm-… #AVCT

Avacta provides a business update ahead of today’s Annual General Meeting of Shareholders, reviewing progress across the portfolio in the first half of 2026 and outlining upcoming milestones. #AVCT avacta.com/year-to-date-b…

In the 3rd Episode of Avacta Academy, our CEO Chris Coughlin and CSO Francis Wilson speak to the CMC team to explain the nuts and bolts of how a drug moves from the lab to being a medicine, and break down the GMP drug manufacturing process. avacta.wistia.com/s/shx67w0ggjx8… #AVCT

In this interview with Ventures Accelerated Life Science, Avacta CEO @coughlin582 shares how Avacta is redefining precision oncology with its tumor-targeted delivery platform, and why this matters for patients, clinicians, and partners. linkedin.com/posts/last-thu… #AVCT

This week we were in London for Venture Road UK 2026, joining the life sciences community to share the progress of our pre|CISION® platform. #AVCT

Avacta is pleased to announce that it has raised gross proceeds of approximately £9 million from institutional investors and existing shareholders. avacta.com/oversubscribed… #AVCT

In this video presentation, Avacta CEO Christina Coughlin reviews the new faridoxorubicin program data. avacta.wistia.com/s/2hfpqeapla3o… #AVCT

Download a copy of the poster at avacta.com/investors/publ… #AVCT

Avacta today released updated Phase 1a/1b and pharmacokinetics, safety, toxicity and preliminary efficacy data with faridoxorubicin at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. avacta.com/avacta-present… #AVCT

Posting of Annual Report and Notice of AGM. avacta.com/posting-of-ann… #AVCT

Avacta today announces that Richard Hughes, one of Avacta’s non-executive Directors, will become non-executive Chairman of Avacta following the Annual General Meeting (AGM) on June 22, 2026. avacta.com/board-director… #AVCT

Avacta today published its unaudited preliminary results for the 12 months ended December 31, 2025. polaris.brighterir.com/public/avacta/… #AVCT

We’re pleased to share the recordings from our Science Day. The presentations explore comparative analyses of pre|CISION® payload delivery with AVA6103 vs approved ADCs, alongside updated in vivo studies of the AVA6207 dual payload delivery system. avacta.com/2026-science-d… #AVCT

Avacta will announce its unaudited preliminary results for the year ended December 31, 2025 on May 19, 2026. avacta.com/notice-of-prel… #AVCT

For those who were unable to attend in person, the event was professionally recorded and the video will be made available on the Avacta website in due course. #AVCT

Thank you to everyone who attended today's Science Day. The whole team really enjoyed being able to present the exciting progress being made and speak to many of you in person. We are so grateful for your continued support! #AVCT